Cargando…

Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?

Interstitial pneumonia with autoimmune features (IPAF) belongs to a group of diseases called interstitial lung diseases (ILDs), which are disorders of a varied prognosis and course. Finding sufficiently specific and sensitive biomarkers would enable the progression to be predicted, the natural histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Miądlikowska, Ewa, Rzepka-Wrona, Patrycja, Miłkowska-Dymanowska, Joanna, Białas, Adam Jerzy, Piotrowski, Wojciech Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745166/
https://www.ncbi.nlm.nih.gov/pubmed/35011819
http://dx.doi.org/10.3390/jcm11010079
_version_ 1784630280174174208
author Miądlikowska, Ewa
Rzepka-Wrona, Patrycja
Miłkowska-Dymanowska, Joanna
Białas, Adam Jerzy
Piotrowski, Wojciech Jerzy
author_facet Miądlikowska, Ewa
Rzepka-Wrona, Patrycja
Miłkowska-Dymanowska, Joanna
Białas, Adam Jerzy
Piotrowski, Wojciech Jerzy
author_sort Miądlikowska, Ewa
collection PubMed
description Interstitial pneumonia with autoimmune features (IPAF) belongs to a group of diseases called interstitial lung diseases (ILDs), which are disorders of a varied prognosis and course. Finding sufficiently specific and sensitive biomarkers would enable the progression to be predicted, the natural history to be monitored and patients to be stratified according to their treatment. To assess the significance of pulmonary fibrosis biomarkers studied thus far, we searched the PubMed, Medline and Cochrane Library databases for papers published between January 2015 and June 2021. We focused on circulating biomarkers. A primary review of the databases identified 38 articles of potential interest. Overall, seven articles fulfilled the inclusion criteria. This review aims to assess the diagnostic and prognostic value of molecules such as KL-6, SP-A, SP-D, circulating fibrocytes, CCL2, CXCL13, CXCL9, CXCL10 and CXCL11. All of these biomarkers have previously been studied in idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated interstitial lung disease (CTD-ILD). IPAF is a disorder of a heterogeneous nature. It explains the lack of coherent observations in terms of correlations with functional parameters. There is still no meta-analysis of pulmonary fibrosis biomarkers in IPAF. This is mainly due to the heterogeneity of the methodology and groups analysed in the research. More research in this area is needed.
format Online
Article
Text
id pubmed-8745166
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87451662022-01-11 Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know? Miądlikowska, Ewa Rzepka-Wrona, Patrycja Miłkowska-Dymanowska, Joanna Białas, Adam Jerzy Piotrowski, Wojciech Jerzy J Clin Med Review Interstitial pneumonia with autoimmune features (IPAF) belongs to a group of diseases called interstitial lung diseases (ILDs), which are disorders of a varied prognosis and course. Finding sufficiently specific and sensitive biomarkers would enable the progression to be predicted, the natural history to be monitored and patients to be stratified according to their treatment. To assess the significance of pulmonary fibrosis biomarkers studied thus far, we searched the PubMed, Medline and Cochrane Library databases for papers published between January 2015 and June 2021. We focused on circulating biomarkers. A primary review of the databases identified 38 articles of potential interest. Overall, seven articles fulfilled the inclusion criteria. This review aims to assess the diagnostic and prognostic value of molecules such as KL-6, SP-A, SP-D, circulating fibrocytes, CCL2, CXCL13, CXCL9, CXCL10 and CXCL11. All of these biomarkers have previously been studied in idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated interstitial lung disease (CTD-ILD). IPAF is a disorder of a heterogeneous nature. It explains the lack of coherent observations in terms of correlations with functional parameters. There is still no meta-analysis of pulmonary fibrosis biomarkers in IPAF. This is mainly due to the heterogeneity of the methodology and groups analysed in the research. More research in this area is needed. MDPI 2021-12-24 /pmc/articles/PMC8745166/ /pubmed/35011819 http://dx.doi.org/10.3390/jcm11010079 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Miądlikowska, Ewa
Rzepka-Wrona, Patrycja
Miłkowska-Dymanowska, Joanna
Białas, Adam Jerzy
Piotrowski, Wojciech Jerzy
Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
title Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
title_full Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
title_fullStr Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
title_full_unstemmed Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
title_short Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features—What Do We Already Know?
title_sort review: serum biomarkers of lung fibrosis in interstitial pneumonia with autoimmune features—what do we already know?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745166/
https://www.ncbi.nlm.nih.gov/pubmed/35011819
http://dx.doi.org/10.3390/jcm11010079
work_keys_str_mv AT miadlikowskaewa reviewserumbiomarkersoflungfibrosisininterstitialpneumoniawithautoimmunefeatureswhatdowealreadyknow
AT rzepkawronapatrycja reviewserumbiomarkersoflungfibrosisininterstitialpneumoniawithautoimmunefeatureswhatdowealreadyknow
AT miłkowskadymanowskajoanna reviewserumbiomarkersoflungfibrosisininterstitialpneumoniawithautoimmunefeatureswhatdowealreadyknow
AT białasadamjerzy reviewserumbiomarkersoflungfibrosisininterstitialpneumoniawithautoimmunefeatureswhatdowealreadyknow
AT piotrowskiwojciechjerzy reviewserumbiomarkersoflungfibrosisininterstitialpneumoniawithautoimmunefeatureswhatdowealreadyknow